Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870519 · ClinicalTrials.gov registry record · Phase 1
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00870519 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 2 participants.
The verdict
NCT00870519, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy subjects.
Interventions
- DRUG I-123-MNI-168
- DRUG 123-I MNI-168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870519
The ClinicalTrials.gov registry entry for NCT00870519 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which I-123-MNI-168 is the first listed.
NCT00870519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00870519 about?
NCT00870519 is a clinical study titled "Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects". The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy subjects.
What is the current status of trial NCT00870519?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2009-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00870519?
The interventions under investigation include: I-123-MNI-168 (DRUG), 123-I MNI-168 (DRUG).
Who is sponsoring clinical trial NCT00870519?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.